Avecho Biotechnology Ltd has released a press release.
Phase III Insomnia Trial Recruitment Update
Filed with ASX ·
6ix hasn’t read this filing yet.
Avecho Biotechnology Limited on 6ix
Earlier from Avecho Biotechnology
- Receipt of R&D Tax Incentive
- Phase III Trial Update - New Sites Commence Recruitment
- March 2025 Quarterly Activities Report & Appendix 4C
- Avecho receives initial US$3M upfront payment from Sandoz
- Avecho and Sandoz enter exclusive license and development agreement to commercialise CBD for insomnia in Australia
Later from Avecho Biotechnology
- June 2025 Quarterly Activities Report & Appendix 4C
- Sleep Health Week: Researchers Recruiting Now for CBD Insomnia Trial
- Appendix 4D and Half-year Financial Report
- Avecho raises $2.5m via placement
- September 2025 Quarterly Activities Report & Appendix 4C
Follow Avecho Biotechnology into a list and get an email when it puts out news.
Follow Avecho Biotechnology